Jake Schechter
Psychiatric/Mental Health · Cheektowaga, NYNPI 1205203403
Payments from drug & device makers
Across 308 payments — averaging $24.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$730
- Teva Pharmaceuticals USA, Inc.$672
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$544
- plus $2K from 9 others
What the payments were for
- Food & beverage$7,45698%
- Education$1562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 63 | $1,663 |
| Johnson & Johnson | 36 | $1,420 |
| Otsuka America Pharmaceutical, Inc. | 41 | $1,007 |
| AbbVie | 37 | $730 |
| Teva Pharmaceuticals USA, Inc. | 29 | $672 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $544 |
| Lundbeck LLC | 31 | $425 |
| E.r. Squibb & Sons, L.L.C. | 13 | $389 |
| Neurocrine Biosciences, Inc. | 9 | $280 |
| Axsome Therapeutics, Inc. | 8 | $169 |
| Janssen Scientific Affairs, LLC | 2 | $149 |
| Gilead | 1 | $90 |
| Neuronetics, Inc. | 2 | $29 |
| Indivior Inc. | 1 | $24 |
| Pfizer | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,039
- ARISTADA$516
- INVEGA SUSTENNA$481
- REXULTI$375
- INVEGA TRINZA$231
- INGREZZA$137
- UZEDY$125
- COBENFY$111
How this compares
$7,612 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 13 | $97,250 |
| AristadaAripiprazole Lauroxil | 22 | $42,989 |
| CaplytaLumateperone Tosylate | 14 | $22,076 |
| VraylarCariprazine Hcl | 18 | $21,144 |
| RexultiBrexpiprazole | 13 | $17,356 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $2,087 |
| Lurasidone Hcl | 24 | $2,007 |
| Bupropion XlBupropion Hcl | 80 | $1,676 |
| Quetiapine Fumarate | 85 | $968 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $878 |
| Prazosin Hcl | 35 | $840 |
| Carbamazepine ErCarbamazepine | 13 | $713 |
| Fluoxetine Hcl | 32 | $650 |
| Buspirone Hcl | 57 | $637 |
| Haloperidol Decanoate | 11 | $581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $672 | $97,25013 claims |
| Alkermes, Inc.Aristada | $1,663 | $42,98922 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $544 | $22,07614 claims |
| AbbVieVraylar | $730 | $21,14418 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,007 | $17,35613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Cheektowaga
- Leah MolinaCheektowaga$12K
- Glenn HannDansville$1.3M
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Mary OlsonNew York$142K
- Elijah StevensBinghamton$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.